By S&S Co. Advocates & Solicitors · Published 24 October 2026 · Informational content, not legal advice: see our disclaimer
Most food businesses brace for an FSSAI problem to start with a lab report, a sample that fails a contamination or composition test, and a notice built around that finding. Two prohibition orders issued on 30 July 2026 show a different and faster route to the same outcome. FSSAI banned Vatave Health Care's FOLINEURO Syrup and halted the sale of Neuherbs TRUE VITAMIN, marketed by Global Healthfit Retail India Private Limited, without pointing to a single contaminated batch or an unsafe ingredient in either product. The problem, in both cases, was the branding.
For a food or health-supplement business, that is a more unsettling kind of enforcement than a composition finding, because it does not depend on what actually went into the bottle or the sachet. It depends on what the name, the packaging, and the category declared on the label suggest to an ordinary buyer, and on whether that suggestion is something the product is actually authorised to claim.
What FSSAI actually objected to
In the FOLINEURO order, FSSAI's stated objection was that the trade name, combined with a brain image displayed prominently on the front label, created a misleading impression that the syrup supported brain and neurological function. Separately, and on its own, the regulator found that the product had been classified and marketed under a category called 'Nutritional Food Supplement', a category that does not exist under the Food Safety and Standards (Health Supplements and Nutraceuticals) Regulations, 2016.
The Neuherbs TRUE VITAMIN order rested on a related but distinct ground. There, the objection was to the trade name itself: 'TRUE VITAMIN' is not a term defined or recognised under the labelling and advertising framework, and FSSAI treated its use as inherently misleading regardless of what claims appeared elsewhere on the pack. Neither order turned on a lab test result. Both turned on what the branding told a buyer, set against what the product was actually permitted to say.
A category that does not exist is itself a violation
The FOLINEURO case illustrates a trap that is easy to miss during product development. The 2016 Health Supplements and Nutraceuticals Regulations set out a defined list of categories a product in this space can be classified under. Picking a category that sounds plausible, descriptive, even reassuring, but that simply does not appear on that list is a violation in itself, independent of whatever the product actually contains or does.
This is a different kind of risk from mislabelling an ingredient or overstating a dosage. A business can get every ingredient declaration right and still fall foul of this ground purely because the regulatory bucket it chose to file the product under is not a bucket the regulations recognise. Checking the declared category against the 2016 Regulations' own list, rather than against what sounds right commercially, is a cheap step that would have caught this before the product ever reached shelves.
Undefined claim terms carry the same risk as false ones
The Neuherbs order makes a related point from a different angle. A claim term does not have to be false to be prohibited. It is enough that the term is not defined or recognised under the Food Safety and Standards (Advertising and Claims) Regulations, 2018 or the Food Safety and Standards (Labelling and Display) Regulations, 2020. 'TRUE VITAMIN' was not accused of being inaccurate so much as being a term the regulatory framework simply has no place for, which FSSAI treated as inherently misleading on its own terms.
For a brand team, this shifts the question away from 'is this claim defensible' and toward 'is this claim or category term one the regulations actually define'. A term that sounds harmless, aspirational, or merely descriptive can still be unusable if it has no recognised basis in the labelling or advertising rules, whatever the marketing upside of using it.
Legal review of a product name tends to focus on trademark clearance, whether the mark is available and distinctive, and stops there. The Neuherbs order is a reminder that a second, separate clearance is needed under food law: whether the name or claim term being adopted has any recognised status under the labelling and advertising regulations at all. A name can clear trademark search comfortably and still be unusable on a food or supplement label for this entirely different reason.
Why this is a faster enforcement tool than a composition finding
A composition-based action, an 'unsafe' or 'substandard' finding, generally has to wait on sampling, splitting the sample, laboratory testing, and often a retest if the operator demands one. That process takes time and gives an operator several procedural points to contest along the way. A branding or naming-based prohibition does not need any of that. FSSAI can act on the label, the packaging imagery, and the declared category as they stand, without waiting for or relying on any test result.
That makes this route quicker for the regulator and harder for a business to anticipate through routine quality control, since quality control is built around testing what is in the product, not auditing what the name and the packaging imply to a buyer who has never opened it. A brand can pass every batch test for months and still face a prohibition order on a day when nothing about the formulation has changed, because the trigger was never in the formulation to begin with.
This also means the usual defences available against a composition-based finding, demanding a retest, challenging how a sample was drawn or split, are largely beside the point here. There is no sample to re-test when the objection is to a brand name or a category label, which narrows a business's options considerably once an order of this kind has already issued.
What a business is required to do once hit with such an order
In the reported cases, FSSAI's order went beyond simply stopping sale. Global Healthfit Retail India was directed to remove the offending claims from both labels and advertising, not just pull the product from shelves, and to submit an Action Taken Report within thirty days confirming compliance. That combination, stop sale, strip the claim everywhere it appears, and report back on a short clock, is a heavier administrative burden than a straightforward recall, since advertising material, e-commerce listings, and packaging already in the supply chain all have to be addressed within the window.
A business on the receiving end of this kind of order should treat the thirty-day reporting window as the operative deadline, not the headline ban itself, since failing to file a credible Action Taken Report on time is its own separate problem on top of the underlying prohibition. Pulling physical stock is the easy part; auditing every digital listing, every marketplace page carrying the old imagery, and any print material already distributed to retailers within thirty days is considerably harder, and is exactly where a hurried compliance response tends to fall short.
A business that cannot complete every step within the window should still file something substantive by the deadline, showing what has been done and what remains, rather than missing the date entirely. An incomplete but honest report is a materially better position than silence.
Checking names, imagery and categories before launch
The practical lesson for a food or supplement brand is to run the product name, the packaging imagery, and the declared regulatory category past the 2016 Health Supplements and Nutraceuticals Regulations and the 2018 Advertising and Claims Regulations before launch, not after a complaint or an inspection raises the question. Composition compliance alone does not protect a product that carries a misleading name, an image implying a benefit the product cannot substantiate, or a category classification the regulations do not recognise.
This review sits apart from the lab-based compliance checks most quality teams already run, and arguably needs a different reviewer altogether, someone looking at the pack and the marketing copy with the same scrutiny a regulator would, rather than someone focused only on what the chemistry shows.
Building this check into the product approval process, alongside trademark clearance and formulation sign-off, costs little next to the alternative. A prohibition order after launch means withdrawing stock that is already in the market, repackaging or rebranding a product that buyers have started to recognise, and absorbing whatever reputational cost comes with a regulator's public order naming the brand. None of that is cheaper than a label review carried out before the first unit ships.
Frequently Asked Questions
Can FSSAI ban a product without any lab finding that it is unsafe?
Yes. Both the FOLINEURO and Neuherbs TRUE VITAMIN prohibitions in July 2026 were based entirely on the product's name, imagery, and declared category, not on any contamination or composition finding. A product can be fully compliant on ingredients and still be prohibited over how it is branded.
What was wrong with FOLINEURO Syrup's labelling specifically?
FSSAI objected to the name combined with a brain image on the front label, which it said created a misleading impression of a brain or neurological benefit, and separately found the product classified under 'Nutritional Food Supplement', a category that does not exist under the 2016 Health Supplements and Nutraceuticals Regulations.
Why was the trade name 'TRUE VITAMIN' itself a problem?
FSSAI treated the term as not defined or recognised under the 2018 Advertising and Claims Regulations or the 2020 Labelling and Display Regulations, and prohibited its use on that basis alone, without needing to show the claim was factually false.
What does a business have to do once FSSAI issues this kind of prohibition order?
Beyond stopping sale, the Neuherbs order required removing the offending claims from both labels and advertising and filing an Action Taken Report within thirty days. Treat that reporting deadline, not just the sale stoppage, as the compliance clock that matters.
How can a brand avoid this kind of enforcement before launch?
Check the product name, packaging imagery, and declared regulatory category against the 2016 Health Supplements and Nutraceuticals Regulations and the 2018 Advertising and Claims Regulations before launch. Composition compliance does not cover branding, and this review needs to be done separately from standard lab-based quality checks.
References & Further Reading
The provisions and rulings below were relied on for this guide. The position can change with amendments and later decisions, so check the current text and the latest case law before acting on any of it.
- Food Safety and Standards (Health Supplements and Nutraceuticals) Regulations, 2016
- Food Safety and Standards (Advertising and Claims) Regulations, 2018
- Food Safety and Standards (Labelling and Display) Regulations, 2020
- FSSAI prohibition order against Vatave Health Care's FOLINEURO Syrup, 30 July 2026
- FSSAI order against Global Healthfit Retail India Private Limited over Neuherbs TRUE VITAMIN, 30 July 2026